key: cord-0985599-a32i5kie
authors: Pryce, Todd M.; Boan, Peter A.; Kay, Ian D.; Flexman, James P.
title: Thermal treatment of nasopharyngeal samples prior to cobas® SARS-CoV-2 testing
date: 2020-08-06
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.07.042
sha: ddd870cdc07bb0419aa1c79a10007461b5f7adc2
doc_id: 985599
cord_uid: a32i5kie

nan

Since the SARS-CoV-2 pandemic, we have seen shortages of diagnostic reagents, 25 consumables and personal protective equipment (PPE) [1, 2] . Initially, we inactivated 26 samples with guanidine hydrochloride (GuHCl) prior to SARS-CoV-2 testing [2, 3] . 27 Following implementation of Roche cobas® SARS-CoV-2 (cobas), we encountered 28 shortages of GuHCl and PPE. To overcome these issues we investigated a number of 29 rapid heat treatment steps prior to cobas testing. Temperatures and durations investigated 30 were based on reports demonstrating the effects of temperature on the viability of SARS- (Table 1 ). Although we observed C T shifts in the cobas E-gene target, the cobas 64 assay is dual-target, therefore the delay in one target may not be critical to the qualitative 

Coronavirus disease (COVID-2019) situation reports

Laboratory Diagnosis of 102 COVID-19: Current Issues and Challenges

Detection of 105 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

SARS-CoV-2 in different environmental conditions

Evaluation of SARS-Coronavirus Decontamination Procedures

Stability 116 and inactivation of SARS coronavirus

Heat sensitivity of a SARS-119 associated coronavirus introduced into plasma products

Methods on Severe Acute Respiratory Syndrome Coronavirus 2 RNA Copy Number

The authors are grateful to Adrian Bautista (Acting Chief Executive of PathWest at the 95 commencement of COVID-19 testing) for provisioning the supply of cobas kits. 96 97